Proteros and Hutchison MediPharma enter into long-term research collaboration agreement
Proteros Biostructures GmbH announced that they entered into a substantial research collaboration agreement with Hutchison MediPharma Limited (HMP), whereby Proteros will support HMP’s drug discovery process throughout 2011 and beyond.
Under the agreement Proteros initially will provide high quality crystallography services on certain projects to support HMP’s drug discovery projects. HMP is focused on the areas of oncology and autoimmune diseases. Proteros will support HMP’s discovery research with Protein-Ligand-structure analysis throughout 2011 and beyond with selected compounds from HMP. This collaboration will significantly accelerate HMP’s drug discovery process, particularly in medicinal chemistry.
Cony D’Cruz, Chief Business Officer and President Proteros US, Inc. stated, “We are very pleased to be selected by Hutchison MediPharma to work with it on its multitude of exciting targets and we believe that our in-depth structural biology expertise is particularly suited to accelerate its efforts in its target areas.”
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Sun Pharma announces closure of merger deal with Ranbaxy

Qualifyze raises $54m to boost supplier risk management in life sciences - With the new funding, Qualifyze aims to expand its operations into the US market
Medivir appoints Vice President, Research & Development Projects
Biogen Idec and Swedish Orphan Biovitrum Update Hemophilia Partnership Agreement
Marijuana component could ease pain from chemotherapy drugs
NOXXON Initiates Phase IIa of Anti-Hepcidin Spiegelmer NOX-H94 - Anemia of Chronic Disease Study is Fourth Phase II Initiated by NOXXON in 2012

Method to reveal undesired biological effects of chemicals - How do pollutants and other chemicals that we are exposed to affect our health?
New Bone Chewing Role for B Cells in Rheumatoid Arthritis

Uncovering Astonishing Benefits of Beef, Chicken, and Pork: New Antioxidants Found!
